Bild

Antigen-specific Induction of Immune Tolerance

The goal of Topas (Tolerizing Particles) is to develop novel therapeutics to treat a variety of immune-mediated and autoimmune diseases. The Topas approach harnesses the natural mechanisms of the liver to promote immune tolerance to blood borne antigens. Small peptide-loaded nanoparticles mimic such blood borne antigens and are taken up by liver sinusoidal endothelial cells (LSECs). LSECs present these antigens to T cells under anti-inflammatory conditions conducive to the induction of tolerogenic regulatory T cells (Tregs).

Tregs are pivotal for immune tolerance, and their therapeutic generation serves to re-instate healthy immune homeostasis and provide a cure for diseases characterized by undesirable or dysregulated inflammatory immune reactions.

Latest News

2017-04-04 – Press release

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

read more …

2016-03-22 – Press release

Evotec spins off auto-immune disease company as ‘Topas Therapeutics GmbH’

read more …

2016-03-22 – Press release

Topas Therapeutics Raises EUR 14 Million to Treat Immunological Disorders

read more …